Vídeos del Professor Bertil Damato
Bertil Damato was born in Malta, where he received his undergraduate training at the University of Malta. In 1987, he obtained his PhD, basing his thesis on monoclonal antibodies to uveal melanoma. In 1993, he moved to the Royal Liverpool University Hospital, where he founded the Liverpool Ocular Oncology Center, which grew into one of the largest ocular oncology services in the world. In 2013, Dr. Damato moved to the University of California, San Francisco, where he was invited to direct the Ocular Oncology Service. He has pioneered various methods of local resection of uveal melanoma, genetic typing of uveal melanoma, ruthenium plaque radiotherapy, and proton beam radiotherapy of iris melanoma. Other research interests include quality of life after treatment of uveal melanoma, vitreoretinal lymphoma, radiotherapy for conjunctival tumors, and a coding system he is developing for retinoblastoma. He has published more than 270 articles, more than 50 chapters, and several textbooks, one as sole author. Dr. Damato is married to Dr. Frankanne Damato, PhD, MBA, and has two children: Erika, an attending ophthalmologist who is specialist in uveitis at Cambridge, UK; and Stephen, an attending pathologist at Oxford, UK. Dr. Damato’s interests include sailing, cycling, and collecting antique ophthalmic textbooks.
While ocular melanoma is rare, it is the most common type of cancer to affect the eye. While it may not not be spoken about as much, it doesn't mean there aren't as many questions about this disease, especially if you've been diagnosed with it or think there's a possibility you may have it. Here to provide expert knowledge about just exactly what ocular melanoma is as well as further fascinating, yet essential, information is internationally-esteemed consultant ophthalmolgist Mr Bertil Damato. If you would like to book an appointment with Mr Damato, you can do so here: https://www.topdoctors.co.uk/doctor/bertil-damato ✔ Follow us on Instagram: https://bit.ly/3fSrqXb ✔ Follow us on Facebook: https://bit.ly/3t5kGsW ✔ Follow us on Twitter: https://bit.ly/39TidKh